Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin with pomalidomide and dexamethasone within its marketing authorisation for treating relapsed or refractory multiple myeloma after 1 or more treatments.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6211

Provisional Schedule

Committee meeting: 1 08 January 2025
Expected publication 19 March 2025

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group Liverpool Reviews and Implementation Group, University of Liverpool

Stakeholders

Companies sponsors GlaxoSmithKline (belantamab mafodotin)
Others Department of Health and Social Care
  Health Technology Wales
  NHS England
Patient carer groups Myeloma UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
  UK Myeloma Society
Assessment group Liverpool Reviews and Implementation Group
Associated public health groups None
Comparator companies Amgen (carfilzomib) (confidentiality agreement signed, participating)
  Janssen-Cilag (bortezomib, daratumumab, teclistamab) (confidentiality agreement signed, participating)
  Menarini Stemline UK (selinexor) (confidentiality agreement signed, participating)
  Takeda (confidentiality agreement signed, participating)
  AbbVie (dexamethasone) (confidentiality agreement not signed, not participating)
  ADVANZ Pharma (dexamethasone0 (confidentiality agreement not signed, not participating)
  AS Kalceks (dexamethasone) (confidentiality agreement not signed, not participating)
  Aspen (dexamethasone) (confidentiality agreement not signed, not participating)
  Aspire Pharma (bortezomib, dexamethasone) (confidentiality agreement not signed, not participating)
  Aurobindo Pharma (bortezomib) (confidentiality agreement not signed, not participating)
  Bausch & Lomb UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Bristol Myers Squibb Pharmaceuticals (pomalidomide) (confidentiality agreement not signed, not participating)
  Dr. Reddy's Laboratories UK (bortezomib) (confidentiality agreement not signed, not participating)
  Glenmark Pharmaceuticals Europe (dexamethasone) (confidentiality agreement not signed, not participating)
  Hameln pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Hospira UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Krka UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Martindale Pharma, an Ethypharm Group Company (dexamethasone) (confidentiality agreement not signed, not participating)
  Medac GmbH (bortezomib) (confidentiality agreement not signed, not participating)
  MSN Laboratories Europe (bortezomib) (confidentiality agreement not signed, not participating)
  Mylan (bortezomib) (confidentiality agreement not signed, not participating)
  Novartis Pharmaceuticals UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Panpharma UK (dexamethasone) (confidentiality agreement not signed, not participating)
  ParaPharm Development (dexamethasone) (confidentiality agreement not signed, not participating)
  Pfizer (bortezomib, elranatamab) (confidentiality agreement not signed, not participating)
  Pharma & (panobinostat) (confidentiality agreement not signed, not participating)
  Ranbaxy UK Limited a Sun Pharmaceutical Company (bortezomib) (confidentiality agreement not signed, not participating)
  Rayner Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)
  Sandoz (bortezomib) (confidentiality agreement not signed, not participating)
  Sanofi (dexamethasone, isatuximab) (confidentiality agreement not signed, not participating)
  Santen UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Synchrony Pharma (dexamethasone) (confidentiality agreement not signed, not participating)
  Teva UK (dexamethasone) (confidentiality agreement not signed, not participating)
  Thame Laboratories (dexamethasone) (confidentiality agreement not signed, not participating)
  Thea Pharmaceuticals (dexamethasone) (confidentiality agreement not signed, not participating)
  Thornton & Ross (bortezomib) (confidentiality agreement not signed, not participating)
  Tillomed Laboratories (bortezomib) (confidentiality agreement not signed, not participating)
  Wockhardt UK (dexamethasone) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health - NI
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
05 June 2024 Invitation to participate
15 March 2024 - 16 April 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6211
15 March 2024 In progress. Scoping commencing
09 November 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-June 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
31 July 2023 Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-March 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission.
23 November 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual